EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 24 IN BIOLOGIC EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SUMMARY RESULTS

被引：0
|
作者：
Marzo-Ortega, Helena [1 ,2 ]
Meroni, Pierluigi [3 ]
Galindez-Agirregoikoa, Eva [4 ]
Behrens, Frank [5 ,6 ]
Bradley, Andrew J. [7 ]
Leage, Soyi Liu [7 ]
Garcia, Miriam [7 ]
Sapin, Christophe [7 ]
Ho, Ji Chen [8 ]
Constantin, Arnaud [9 ]
Hall, Stephen [10 ]
机构：
[1] Univ Leeds, Leeds Teaching Hosp Trust, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England
[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[3] Univ Milan, Ist Auxol Italiano, Milan, Italy
[4] Univ Hosp Basurto, Serv Reumatol, Bilbao, Spain
[5] Goethe Univ Frankfurt, Div Rheumatol, Frankfurt, Germany
[6] Goethe Univ Frankfurt, IME Fraunhofer Project Grp Translat Med & Pharmac, Frankfurt, Germany
[7] Eli Lilly & Co, Lilly Int, Indianapolis, IN 46285 USA
[8] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan
[9] Hosp Pierre Paul Riquet, Dept Rheumatol, Toulouse, France
[10] Monash Univ, Dept Med, Clayton, Vic, Australia
来源：
RHEUMATOLOGY | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O03
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of ixekizumab at week 24 in biologic-experienced patients with active psoriatic arthritis: summary results
    Marzo-Ortega, H.
    Meroni, P.
    Galindez-Agirregoikoa, E.
    Behrens, F.
    Bradley, A.
    Leage, S. Liu
    Garcia, M.
    Sapin, C.
    Ho, J.
    Constantin, A.
    Hall, S.
    Porsdal, V.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 43 - 44
  • [2] EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 52 IN BIOLOGIC NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (SPIRIT-P1)
    Lespessailles, Eric
    Kirkham, Bruce
    Nebro, Antonio Fernandez
    Blanco, Ricardo
    Strehblow, Christoph
    Inciarte-Mundo, Jose
    Porsdal, Vibeke
    Garcia, Miriam
    Kurzawa, Monika
    Sapin, Christophe
    Geusens, Piet
    Goupille, Philippe
    Tahir, Hasan
    RHEUMATOLOGY, 2018, 57
  • [3] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
    Mease, Philip J.
    Okada, Masato
    Kishimoto, Mitsumasa
    Shuler, Catherine L.
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan R.
    Lee, Chin H.
    Gladman, Dafna D.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Efficacy and safety of ixekizumab at week 52 in biologic-naive patients with active psoriatic arthritis (SPIRIT-P1)
    Lespessailles, E.
    Kirkham, B.
    Nebro, A.
    Alonso, R.
    Strehblow, C.
    Inciarte, J.
    Porsdal, V.
    Garcia, M.
    Kurzawa, M.
    Sapin, C.
    Geusens, P.
    Goupille, P.
    Tahir, H.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 : 44 - 45
  • [5] Intravenous Golimumab in Adult Patients with Active Psoriatic Arthritis: Efficacy and Safety through Week 24
    Kavanaugh, Arthur
    Husni, M. Elaine
    Harrison, Diane D.
    Kim, Lilianne
    Lo, Kim Hung
    Hsia, Elizabeth C.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [6] INTRAVENOUS GOLIMUMAB IN ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: EFFICACY AND SAFETY THROUGH WEEK 24
    Kavanaugh, A.
    Husni, M. E.
    Harrison, D. D.
    Kim, L.
    Lo, K. H.
    Hsia, E. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 671 - 672
  • [7] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Mease, P. J.
    Okada, M.
    Kishimoto, M.
    Shuler, C. L.
    Carlier, H.
    Lin, C. -Y.
    Mou, J.
    Moriarty, S. R.
    Lee, C. H.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 96 - 96
  • [8] Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
    Klavdianou, Kalliopi
    Lazarini, Argyro
    Grivas, Alexandros
    Tseronis, Dimitrios
    Tsalapaki, Christina
    Rapsomaniki, Panagiota
    Antonatou, Katerina
    Thomas, Konstantinos
    Boumpas, Dimitrios
    Katsimbri, Pelagia
    Vassilopoulos, Dimitrios
    FRONTIERS IN MEDICINE, 2020, 7
  • [9] 52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Okada, Masan
    Kishimoto, Mitsumasa
    Shuler, Catherine
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 925 - 925
  • [10] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
    van der Heijde, Desiree
    Gladman, Dafna D.
    Kishimoto, Mitsumasa
    Okada, Masato
    Rathmann, Suchitrita S.
    Moriarty, Susan R.
    Shuler, Catherine L.
    Carlier, Hilde
    Benichou, Olivier
    Mease, Philip J.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (03) : 367 - 377
12345